Compounds for treatment of cardiac arrhythmias and heart failure

A compound, or a stereoisomer, tautomer, pharmaceutically acceptable salt, hydrate, or solvate thereof, according to the formula

• wherein:
• RB is H, aliphatic, —O-aliphatic, —S-aliphatic, —O—C(O)-aliphatic, or halogen;
• RC is H or aliphatic;
• RD is —(CR72)n-X-(CR72)m-N(R4)R5, —(CH2)qSO3M, —(CH2)qNH2, or —(CH2)qOH;
• RE is H, —O-aliphatic, aliphatic, —S-aliphatic, —O—C(O)-aliphatic, or halogen;
• Q is C-R3;
• X is N(R6);
• R1 and R2 independently are H or aliphatic;
• R3 is H, aliphatic, —O-aliphatic, or —S-aliphatic;
• R4 and R5 independently are H, aliphatic, aryl or heteroaryl, or R4 and R5 together with N form a heterocycloaliphatic or heteroaryl ring;
• R6 is H or aliphatic;
• each R7 independently is H, halogen, or aliphatic;
• M is a monatomic cation;
• and
• m, n, and q independently are integers from 1 to 10,
• wherein if RD is —(CR72)nX—(CR72)m—N(R4)R5, then at least one of the following conditions applies
• (i) at least one of R1 and R2 is other than H, or
• (ii) at least one of RC and RE is other than H, or
• (iii) X is other than N(H), or
• (iv) m is not 2, or
• (v) n is not 1, or
• (vi) if Q is CH then RB is not —O-aliphatic, or
• (vii) if RB is H then Q is not C-R3 where R3 is —O-aliphatic, and
• wherein the compound is not.